Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571)

Internal Medicine

Volumn 42, Issue 8, 2003, Pages 740-742

  Naito, Kotaro ^a   Mori, Takehiko ^a   Miyazaki, Keiko ^a   Tsukada, Yuiko ^a   Ikeda, Yasuo ^a   Okamoto, Shinichiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic myelogenous leukemia; Extramedullary blast crisis; Imatinib mesylate; Lymph node

Indexed keywords

ALPHA INTERFERON; CYTARABINE 5' STEARYLPHOSPHATE; IMATINIB;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; BONE MARROW; BONE MARROW TRANSPLANTATION; CASE REPORT; CELL INFILTRATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DONOR; EDEMA; FEBRILE NEUTROPENIA; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA REMISSION; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; METAPHASE; MYELOBLAST; NECK; PHILADELPHIA 1 CHROMOSOME; POSTOPERATIVE PERIOD; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0042473985     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.740     Document Type: Article

References (13)

1. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: Analysis of 242 patients. Am J Med 83: 445-454, 1987.
2. Cervantes F, Rozman M, Rosell J, Urbano-Ispizua A, Montserrat E, Rozman C. A study of prognostic factors in blast crisis of Philadephia chromosome-positive chronic myelogenous leukemia. Br J Haematol 76: 27-32, 1990.
3. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors affecting duration of survival after onset of blast formation of chronic myeloid leukemia. Blood 99: 2304-2309, 2002.
4. Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ. Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease. Cancer 59: 297-300, 1987.
5. Inverardi D, Lazzarino M, Morra E, et al. Extramedullary disease in Ph'-positive chronic myelogenous leukemia: frequency, clinical features and prognostic significance. Haematologica 75: 146-148, 1990.
6. Specchia G, Palumbo G, Pastore D, Mininni D, Mestice A, Liso V. Extramedullary blast crisis in chronic myeloid leukemia. Leuk Res 20: 905-908, 1996.
7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
8. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of the chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001.
9. Kantarjian HM, Cortes J, O'Brien SG, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99: 3547-3553, 2002.
10. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539, 2002.
11. Visani G, Rosti G, Bandini G, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol 109: 722-728, 2000.
12. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 61: 1765-1774, 2001.
13. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119: 106-108, 2002.